Insights into Coherus Oncology Q4 Earnings
Benzinga·03/09/2026 20:18:06
Listen to the news
The Q4 earnings report for Coherus Oncology (NASDAQ:CHRS) was released on Monday, March 9, 2026 at 04:05 PM.
Here's what investors need to know about the latest announcement.
Earnings
Coherus Oncology missed estimated earnings by 0.0%, reporting an EPS of $-0.34 versus an estimate of $-0.34.
Revenue was down $41.40 million from the same period last year.
Past Earnings Performance
During the previous quarter, the company missed on EPS by $0.01, leading to a 10.07% drop share price change the next day.
Here's a look at Coherus Oncology's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.32 | -0.26 | -0.13 | -0.13 |
| EPS Actual | -0.33 | -0.34 | -0.35 | -0.28 |
| Revenue Estimate | 12.93M | 9.62M | 54.70M | 43.88M |
| Revenue Actual | 11.57M | 10.25M | 7.60M | 54.14M |
To track all earnings releases for Coherus Oncology visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.